PathMaker Neurosystems is a clinical-stage neurotechnology company that is focused on commercializing a breakthrough, non-invasive approach to treating ALS in the at-home setting using disease-modifying technology that slows disease progression, improves motor function and increases survival. PathMaker’s proprietary multi-site direct current stimulation technology (Multi-Site DCS) works through a dual mechanism of action that suppresses motor neuron hyperexcitability while enhancing degradation of cytoplasmic aggregates of TDP-43 and SOD1 proteins that accumulate in motor neurons of people with ALS.  With extensive published pre-clinical mechanistic studies, our second ALS clinical trial now underway, and recent receipt of FDA Breakthrough Device Designation for the treatment of ALS, we have refined our commercialization roadmap to get to rapid FDA De Novo clearance and the start of revenues on our lead product, MyoRegulator®.